ETCTN Trials by Disease/ Treatment Area: Breast Cancer

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: June 12, 2019

Breast Cancer

Early stage TNBC

Locally advanced/ metastatic TNBC

Triple negative breast cancer (TNBC)

Hormone receptor positive (HR+)

Locally advanced/ metastatic ER+ and/or PR+/HER2

Locally advanced/ metastatic ER+/HER2-

Non HER2 positive with BRCA mutation

With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)

Expansion: Locally advanced/ metastatic HER2-

Bone metastatic breast cancer (TNBC or ER+ and/or PR+)

HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

TNBC or HR+

PTEN or PIK3CB mutation (TNBC or ER+ or HER2-)

Locally advanced/ metastatic ER+ and/or PR+

Non HER2 positive with BRCA mutation

With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)

Expansion: Locally advanced/ metastatic HER2-

Bone metastatic breast cancer (TNBC or ER+ and/or PR+)

HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: June 12, 2019